Drug intelligence / Profile preview

HRT1

Development stage: Preclinical
Lead developer: Daré Bioscience
Modality: Peptides

Overview

HRT1 is a novel cardiac peptide therapeutic being developed by TwoToBiotech for the treatment of cardiac and metabolic diseases, specifically focusing on glucose metabolism disorders. It is described as a peptide hormone naturally involved in the regulation of glucose homeostasis. While the specific molecular target and detailed mechanism of action have not been publicly disclosed, HRT1 is positioned as a potential treatment for conditions such as type 2 diabetes and related metabolic syndromes where glucose regulation is impaired.

Beyond the preview

Go deeper on HRT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRT1.

Explore the full profile